NASDAQ:CRDL Cardiol Therapeutics (CRDL) Stock Price, News & Analysis $1.11 -0.04 (-3.48%) Closing price 07/15/2026 04:00 PM EasternExtended Trading$1.09 -0.02 (-1.71%) As of 05:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cardiol Therapeutics Stock (NASDAQ:CRDL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cardiol Therapeutics alerts:Sign Up Key Stats Today's Range$1.08▼$1.1850-Day Range$0.99▼$1.3752-Week Range$0.88▼$1.71Volume719,150 shsAverage Volume527,729 shsMarket Capitalization$127.92 millionP/E RatioN/ADividend YieldN/APrice Target$8.50Consensus RatingHold Company Overview Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease. CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes. The company is preparing to initiate further Phase 2 trials in patients with heart failure and preserved ejection fraction to explore the potential of CBD-based therapy to reduce hospitalization rates and improve quality of life. In parallel, Cardiol is investigating novel cyclic dinucleotide immunomodulators designed to recalibrate the innate immune response in cardiovascular settings. Headquartered in Toronto, Canada, Cardiol Therapeutics operates multiple clinical and research collaborations across North America and Europe. Founded in 2017 and rebranded in 2019 after acquiring its core CBD assets, the company is led by Executive Chairman Peter Hamilton, a seasoned life-science executive, alongside a management team with deep expertise in drug development, regulatory affairs, and cardiovascular research. Cardiol’s strategy emphasizes translational science and collaborative clinical programs to address critical unmet needs in heart disease.AI Generated. May Contain Errors. Read More Cardiol Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreCRDL MarketRank™: Cardiol Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 1319th out of 1,702 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingCardiol Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCardiol Therapeutics has a consensus price target of $8.50, representing about 665.8% upside from its current price of $1.11.Amount of Analyst CoverageCardiol Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Cardiol Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Cardiol Therapeutics are expected to remain at ($0.31) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cardiol Therapeutics is -3.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cardiol Therapeutics is -3.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCardiol Therapeutics has a P/B Ratio of 10.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cardiol Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.03% of the float of Cardiol Therapeutics has been sold short.Short Interest Ratio / Days to CoverCardiol Therapeutics has a short interest ratio ("days to cover") of 6.52.Change versus previous monthShort interest in Cardiol Therapeutics has recently increased by 6.41%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCardiol Therapeutics does not currently pay a dividend.Dividend GrowthCardiol Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.62 News SentimentCardiol Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Cardiol Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows5 people have added Cardiol Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cardiol Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.25% of the stock of Cardiol Therapeutics is held by insiders.Percentage Held by Institutions12.49% of the stock of Cardiol Therapeutics is held by institutions.Read more about Cardiol Therapeutics' insider trading history. Receive CRDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRDL Stock News HeadlinesCardiol Therapeutics’ Phase II Pericarditis Data in JAHA Bolsters Near-Complete Phase III MAVERIC TrialJuly 14 at 4:50 PM | tipranks.comCardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart AssociationJuly 14 at 7:27 AM | prnewswire.comBuy this stock tomorrowMarc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership with Nvidia - one he believes positions it ahead of Tesla in the autonomous vehicle race. With a market-moving announcement expected on July 31st, Chaikin is urging investors to swap overpriced AI stocks for this under-the-radar name before markets open. He's also releasing a free Hotlist and Hitlist of buy and sell ideas for the second half of 2026. | Chaikin Analytics (Ad)Cardiol Therapeutics to Highlight CardiolRx Programs at B. Riley Mind, Muscle & Vision SummitJuly 9, 2026 | tipranks.comCardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision SummitJuly 9, 2026 | prnewswire.comCardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of ShareholdersJune 26, 2026 | finanznachrichten.deCardiol Therapeutics Reports Results of 2026 Annual General Meeting of ShareholdersJune 25, 2026 | prnewswire.comCardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDTJune 23, 2026 | prnewswire.comSee More Headlines CRDL Stock Analysis - Frequently Asked Questions How have CRDL shares performed this year? Cardiol Therapeutics' stock was trading at $0.9538 on January 1st, 2026. Since then, CRDL stock has increased by 16.4% and is now trading at $1.11. How were Cardiol Therapeutics' earnings last quarter? Cardiol Therapeutics Inc. (NASDAQ:CRDL) released its earnings results on Monday, May, 11th. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.07). How do I buy shares of Cardiol Therapeutics? Shares of CRDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cardiol Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiol Therapeutics investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings5/11/2026Today7/15/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2d) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 As of 2 days ago, CRDL's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRDL CIK1702123 Webwww.cardiolrx.com Phone(289) 910-0850FaxN/AEmployees20Year Founded2017Price Target and Rating Average Price Target for Cardiol Therapeutics$8.50 High Price Target$9.00 Low Price Target$8.00 Potential Upside/Downside+665.8%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-229.43% Return on Assets-165.60% Debt Debt-to-Equity RatioN/A Current Ratio4.39 Quick Ratio4.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book10.09Miscellaneous Outstanding Shares115,245,000Free Float109,195,000Market Cap$127.92 million OptionableNot Optionable Beta0.74 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:CRDL) was last updated on 7/16/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredJeff Brown and Marc Chaikin's latest AI prediction explainedJeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...Brownstone Research | SponsoredURGENT Dollar Reset Warning for MondayA 50-year U.S.-Saudi arrangement established under Henry Kissinger - one credited with anchoring the dollar in...Golden Portfolio | SponsoredWhat will Nvidia do next?Wall Street spends millions on supercomputers and analyst teams to forecast stock prices. Now a new predictive...TradeSmith | SponsoredBlackRock just moved $150 billion into this "new internet"BlackRock CEO Larry Fink's 2026 chairman's letter compared tokenization to the birth of the internet - and the...Awesomely, LLC | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRDL Stock Alerts